DECIBEL THERAPEUTICS INC's ticker is DBTX and the CUSIP is 24343R106. A total of 39 filers reported holding DECIBEL THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $46,162 | +27.5% | 11,990 | 0.0% | 0.00% | – |
| Q1 2023 | $36,210 | +47.3% | 11,990 | 0.0% | 0.00% | – |
| Q4 2022 | $24,580 | -40.0% | 11,990 | 0.0% | 0.00% | – |
| Q3 2022 | $41,000 | -18.0% | 11,990 | 0.0% | 0.00% | -100.0% |
| Q2 2022 | $50,000 | +38.9% | 11,990 | 0.0% | 0.00% | – |
| Q1 2022 | $36,000 | -48.6% | 11,990 | -20.3% | 0.00% | -100.0% |
| Q4 2021 | $70,000 | -39.7% | 15,053 | 0.0% | 0.00% | – |
| Q3 2021 | $116,000 | -33.7% | 15,053 | -25.9% | 0.00% | -100.0% |
| Q2 2021 | $175,000 | -38.4% | 20,305 | -18.8% | 0.00% | -50.0% |
| Q1 2021 | $284,000 | – | 25,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 3,139,685 | $9,545,000 | 2.59% |
| Samsara BioCapital, LLC | 826,422 | $2,512,000 | 0.63% |
| Orbimed Advisors | 4,945,192 | $15,033,000 | 0.24% |
| Alphabet Inc. | 1,636,258 | $4,974,000 | 0.16% |
| HARVARD MANAGEMENT CO INC | 328,798 | $1,000,000 | 0.10% |
| Casdin Capital, LLC | 330,000 | $1,003,000 | 0.04% |
| Bronte Capital Management Pty Ltd. | 163,224 | $496,000 | 0.04% |
| MYDA Advisors LLC | 20,000 | $61,000 | 0.02% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 263,600 | $801,000 | 0.02% |
| ATLAS CAPITAL ADVISORS LLC | 41,025 | $124,716,000 | 0.02% |